Press coverage about Ocera Therapeutics (NASDAQ:OCRX) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Ocera Therapeutics earned a news impact score of 0.10 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 45.5293510090387 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Shares of Ocera Therapeutics (OCRX) traded down $0.01 during trading on Tuesday, hitting $1.70. 433,900 shares of the stock were exchanged, compared to its average volume of 1,166,617. Ocera Therapeutics has a 52 week low of $0.52 and a 52 week high of $2.95.

A number of equities analysts have commented on the stock. Zacks Investment Research cut shares of Ocera Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, November 8th. HC Wainwright cut shares of Ocera Therapeutics from a “buy” rating to a “neutral” rating and set a $1.75 price objective for the company. in a research report on Friday, November 3rd. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company. Ocera Therapeutics presently has an average rating of “Hold” and a consensus price target of $1.69.

COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Ocera Therapeutics (OCRX) Share Price” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another publication, it was stolen and reposted in violation of United States & international copyright laws. The original version of this news story can be accessed at

Ocera Therapeutics Company Profile

Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.

Insider Buying and Selling by Quarter for Ocera Therapeutics (NASDAQ:OCRX)

Receive News & Stock Ratings for Ocera Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocera Therapeutics Inc and related stocks with our FREE daily email newsletter.